focus -WSS

focus

author：knowledge 2025-09-30 16:25:03 - browse：69583

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Parkinson’s finding may lead to tests and, someday, treatments

leisure time

WSS

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Florida babysitter arrested over hot car death, authorities say

Why Marc Tessier

It's time to take a new tack for treating Alzheimer's

The tragedy of Johnson & Johnson’s Covid vaccine

Research misconduct: Proposed new rules face resistance

hotspot

focus

leisure time

Medicare details structure of new drug price negotiation program

Prosecutors say FTX founder Sam Bankman

The cancer drug shortage isn’t new — and neither are the solutions

AI generated plenty of interest at JPM but not a lot of trust

Jerome Adams on the need for new antivirals for Covid

Why Marc Tessier

Walensky prepares to leave CDC — and Congress — behind

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Drug repurposing or repositioning? The language matters

'The View' co

hotspot

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

New chief aims to remake Sanofi Genzyme

Test for long Covid? Researchers find new clue in blood samples

A new deal aims to ramp up use of AI in rehab care decisions

The tragedy of Johnson & Johnson’s Covid vaccine

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

hotspot

entertainment

leisure time

leisure time